Lederfolin

Phase 2Small molecule

UUniversity of Pisa

Lederfolin is one of 39 small molecule programs targeting Locally-advanced Rectal Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Locally-Advanced Rectal CancerActive, not recruiting

Locally-Advanced Rectal CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

48 competitors in Locally-Advanced Rectal Cancer

#DrugCompanyPhaseTrials

Eloxatin

Teva

Phase 3

28 2

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

45 3

Beyfortus

BeiGene

Phase 3

9 4

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

6 5

Jemperli

GGlaxo Dba Glaxosmithkline

Phase 3

4 6

Camptosar

Pfizer

Phase 2

7 7

Avastin

Roche

Phase 2

7 8

Mfolfirinox

Incyte

Phase 3

2 9

FOLFOX

AstraZeneca

Phase 3

2 10

Keytruda

Merck & Co.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Active, not recruiting

Locally-Advanced Rectal Cancer

NCT05253846

Clinical

Trials by Indication[1]

Transplantation1 trial

Xenotransplantation of Primary Cancer Samples in Zebrafish Embryos

Unknown status·UUniversity of Pisa··NCT03668418·120 enrolled

Locally-advanced Rectal Cancer1 trial

Phase II Study of Short-course Radiotherapy Followed by Consolidation Chemotherapy With the Triplet FOLFOXIRI as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: the ShorTrip Study

Active, not recruiting·GGruppo Oncologico del Nord-Ovest·Phase 2·NCT05253846·63 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Lederfolin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lederfolin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lederfolin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Pisa company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Pisa

Lederfolin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Transplantation1 trial

Locally-advanced Rectal Cancer1 trial

References

Drug Info

Quick Facts

Related News